They have to repay substantial debt in 2011 I think and albuferon, lupus drugs are iffy. In addition, they were supposed to get 160 mil for abthrax from the government this year but payment has been delayed which added to uncertainty. They've had numerous clinical failures in their past so this could be their last chance. Bad profile for this market.